MedPath

Injection of 99mTc-nanocolloid and ICG to identify, retrieve and qualify tumor draining lymph nodes in early-stage lungcancer

Recruiting
Conditions
10038666
10029107
lung tumor
early-stage lung cancer
lung nodule
Registration Number
NL-OMON51465
Lead Sponsor
Radboud Universitair Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

Suspected (operable) lung tumor of 1 to 5 cm that is referred for diagnosis by
a navigation bronchoscopy.

Exclusion Criteria

Allergic to 99mTc-nanocolloid or ICG.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The primary objective is to determine the feasibility of identifying and<br /><br>analyzing the TDLN in patients with NSCLC (cT1 to cT2b) on SPECT/CT-imaging and<br /><br>during surgical resection using a radioactive and fluorescent tracer. To verify<br /><br>the objective, injections (at multiple locations by repositioning of the<br /><br>catheter) should be feasible during a navigation bronchoscopy using<br /><br>99mTc-nanocolloid and peri-surgically (through trans-thoracic needle or<br /><br>navigation bronchoscopy) using ICG and the drainage of these tracers should be<br /><br>visible on either SPECT/CT-imaging or a fluorescent camera. Feasibility of<br /><br>identification are qualitative and quantitative (how many nodes on imaging and<br /><br>surgery) endpoints that will be assessed by consensus between a pulmonary<br /><br>physician, technical physician, nuclear physician and a cardiothoracic surgeon<br /><br>that are part of the study team.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>The quality of drainage after intra- or peritumoral injections, the Pioneer<br /><br>Plus catheter as endobronchial catheter for sampling, injection and use of the<br /><br>real-time ultrasound-imaging, the removal of SLN during surgery based on<br /><br>fluorescence, the added value of the additional pathological evaluation and the<br /><br>immunological reactions found in the SLN and tumor.</p><br>
© Copyright 2025. All Rights Reserved by MedPath